source
- Lilly’s retatrutide data at ADA 2026 underscores its lead in obesity drug marketThe American Diabetes Association’s 2026 meeting highlighted a wave of new weight‑loss drug data as companies vie for a slice of a market dominated by Eli Lilly and Novo Nordisk. Lilly presented r…
- Incyte to acquire Vega Therapeutics for up to $2 billion, securing late-stage von Willebrand disease drugIncyte announced it will purchase Vega Therapeutics, a unit of Star Therapeutics, for $1.25 billion in cash with the possibility of receiving up to $750 million more if future sales targets are met…